Value through Innovation10 October 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Boehringer Ingelheim Animal Health announces winners of the 2015 European PRRS Research Award


Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study


Delayed IPF diagnosis negatively impacts patients by delaying treatment according to global survey of pulmonologists1


New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF


VARGATEF® plus docetaxel significantly reduced tumour burden in lung cancer patients with advanced adenocarcinoma compared to docetaxel alone


ECC 2015: GIOTRIF® (afatinib) demonstrates superior survival compared to Tarceva® (erlotinib) for patients with previously treated advanced squamous cell carcinoma of the lung, independent of EGFR mutation status


CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)


New data show only 40% of physicians treating advanced lung cancer considered extension of life to be the most important treatment goal after first-line chemotherapy


Boehringer Ingelheim Animal Health launches two new swine vaccines in Europe


ERS 2015: Landmark year for Boehringer Ingelheim’s respiratory portfolio - new data for COPD, IPF and asthma treatments


Boehringer Ingelheim and BioMed X apply crowdsourcing to establish a team of scientists for identifying key epigenetic regulators of COPD


Jardiance® is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial


Asthma: U.S. FDA approves new indication for SPIRIVA® Respimat®


Type 2 diabetes: International survey shows quality of patient-physician conversation at diagnosis linked to better patient outcomes


EASD: Additional Evidence Showed ABASAGLAR® (insulin glargine) Provided Safety and Efficacy Similar to Lantus®


New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer


European Medicines Agency (EMA) approves the use of Ingelvac CircoFLEX® during pregnancy and lactation in sows


Boehringer Ingelheim licenses Vectron Biosolutions’ expression technology platform

back 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16